Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT) (TangRO)
Hereditary hemorrhagic telangiectasia (HHT) results from genetic deregulation of angiogenesis. It is characterized by mucocutaneous telangiectasia responsible for recurrent epistaxis affecting quality of life (anaemia, iron deficiency, social distress). More rarely, HHT is complicated by the appearance of pulmonary, hepatic or cerebral arteriovenous malformations that can lead to serious complications: cerebrovascular accidents, cerebral abscesses, high output heart failure, and massive hemoptysis (1). The intensity of symptoms increases with age but with significant individual variability, even for the same mutation in the same family. Thus, while the mutations responsible for the disease have been identified, the pathophysiology is not fully understood because these mutations do not explain the great diversity of clinical presentations. Other factors not yet identified probably play an important role. Angiogenic T cells (TANG) are a newly individualized T cell population, defined by a CD4+CXCR4+CD31+ phenotype, which plays a key role in differentiating endothelial progenitors (2).
In an earlier study, the investigators showed that patients with HHT had a decrease in CD4+ and CD8+ LT compared to a cohort of healthy subjects (3).
They hypothesize that the lymphopenia mainly involves TANG, whose quantification could make it possible to assess the individual level of angiogenesis during HHT. The evaluation of the TANG levels could thus make it possible to personalize HHT management.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Dijon, France, 21079
- CHU Dijon Bourgogne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Person who has given consent
- Adult
- Person capable of understanding spoken and written French
"Patient" group:
- Certain HHT (3 or 4 Curacao criteria - Appendix 2):
- Recurring epistaxis
- Telangiectasia of the skin or mouth
- Family hereditary context
- Arteriovenous visceral malformations
- Causal mutation identified
- Person capable of completing monthly epistaxis charts
"Control" group :
- Control subjects will be matched to patients for age (+/- 6 years) and sex.
Exclusion Criteria:
- Person not affiliated to a national health insurance scheme
- Pregnant or breastfeeding woman
- Protected adult
- Hemoglobin levels less than 9 g/dl in the last 15 days
- Progressive or recent infectious disease, autoimmune disease or cancer (less than 6 months)
- Immunosuppressive treatment in progress or recent (less than 6 months), including systemic steroid therapy. The use of inhaled or topical steroids is not an exclusion criterion.
Treatment in progress or stopped less than 6 months ago or to be introduced within the next 3 months of the following medications:
- bevacizumab
- tranexamic acid
- dipeptidyl peptidase 4 inhibitors (diabetic patient)
- beta-blockers (hypertensive patient)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients
Hereditary hemorrhagic telangiectasia patients
|
Three monthly epistaxis charts to be completed
|
|
Controls
Matched for age (+/- 5 ans) and sex.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Average monthly duration (in minutes) of epistaxis over the 3 months following inclusion
Time Frame: Through study completion, an average of 3 months
|
Through study completion, an average of 3 months
|
|
Number/mm3 of circulating TANG (CD3+CXCR4+CD31+) at inclusion.
Time Frame: At inclusion
|
At inclusion
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GUILHEM AMRO/AOI 2017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.